SignalXSignalX

ARWR ARROWHEAD PHARMACEUTICALS, INC.

Q4 2025 10-Q
Filed: Feb 5, 2026Period ending Dec 31, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
ARROWHEAD PHARMACEUTICALS, INC. Overview

ARROWHEAD PHARMACEUTICALS, INC. (ARWR) 10-Q quarterly report for Q4 2025, filed with SEC EDGAR on Feb 5, 2026 for the fiscal period ending Dec 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q4 2025 10-Q

Management Discussion & Analysis

  • • Revenue $264.0M for Q1 FY2026, up $261.5M YoY from $2.5M in Q1 FY2025, driven by Sarepta, Novartis, Sanofi license agreements
  • • Operating income $40.8M vs operating loss $(161.4)M YoY; net income $30.8M vs net loss $(173.1)M YoY; net income per diluted share $0.22 vs $(1.39)
+3 more insights

Risk Factors

  • • No new risk factors added this quarter compared to fiscal 2025 10-K
  • • Most material risks remain consistent with those in fiscal 2025 10-K filing
+3 more insights

Get deeper insights on ARROWHEAD PHARMACEUTICALS, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.